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ABSTRACT
BACKGROUND: Gestational trophoblastic diseases (GTD) result from abnormal proliferation of trophoblastic tissue and 
although rare, are a recognizable cause of maternal morbidity and mortality worldwide. However, prognosis is good when 
diagnosed and treated early.
OBJECTIVES: To describe the prevalence, pattern of presentation, management practices and outcome of Gestational 
Trophoblastic Diseases at the University of Abuja Teaching Hospital, Abuja, Nigeria.
MATERIALS AND METHODS: Case notes of women with a diagnosis of Gestational Trophoblastic Disease from 1st January 
2009 and 31st December 2016 were retrospectively reviewed. Relevant information was extracted and entered into 
structured proformas. The data processing and analysis was done with the aid of SPSS for windows version 20.0. Results 
were expressed as percentages, means and range.
RESULTS: A total of 51 cases of Gestational Trophoblastic Diseases were reviewed, giving a prevalence rate of 4.4/1000 
deliveries. The prevalence of molar pregnancy and choriocarcinoma were 2.4 and 1.6 per thousand deliveries respectively. 
The age group with the highest frequency of occurrence was the 25-29 years {18(35.3%)} and 25(49%) were para 1-4. The 
commonest antecedent pregnancy event was a miscarriage in 74.5% of cases while the commonest symptoms were 
amenorrhoea 46(90.2%) and vaginal bleeding 45(88.2%). These were complicated by anaemia in 18(35.5%) of cases. Thirty 
(58.8%) women had suction evacuation, 16(31.4%) had chemotherapy and 3(5.9%) had hysterectomy. Loss to follow up was 
33(64.7%) and case fatality rate was 19.6%.
CONCLUSION:  Morbidity and mortality resulting from Gestational Trophoblastic Diseases is still high in University of Abuja 
Teaching Hospital, Abuja. Significant contributing factors were late presentation and poor compliance. Efforts have to be 
made to reeducate patients and health workers so as to address challenges related to early diagnosis and compliance. 
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Original Article 
INTRODUCTION
estational trophoblastic diseases (GTDs) 
Grefer to a wide spectrum of benign and malignant disorders resulting from 
abnormal proliferation of trophoblastic tissue and 
although rare, they are a recognizable cause of 
1
maternal morbidity and mortality world wide . 
One characteristic however that makes them 
unique  i s  the ir  s ignicant  response  to 
chemotherapy and a cure rate exceeding 90%. 
This allows affected women who are within child 
bearing age to achieve their reproductive 
2
potential.
The World Health Organization (WHO) classied 
gestational trophoblastic diseases into benign 
conditions like hydatidiform mole (HM) (partial, 
complete,  and invasive mole) ,  tumours 
(gestational choriocarcinoma, placental site 
t r o p h o b l a s t i c  t u m o u r  a n d  e p i t h e l i o i d 
trophoblast ic  tumour)  and tumour- l ike 
conditions (exaggerated placental site, placental 
site nodule or plaque). Also, hydatidiform mole is 
further classied as villous or non-villous GTD 
1,3based on pathology  and the tumours or 
malignant forms of the disease are also referred to 
as Gestational Trophoblastic Neoplasia (GTN).  
These tumours, depending on the stage have 
3,4,5effects on local tissues or on distant organs. 
Gestational Trophoblastic Neoplasia most 
commonly are a  complicat ion of  molar 
pregnancy, however they may also follow other 
pregnancy events like miscarriages, ectopic 
4pregnancy or term pregnancy.  Therefore, by 
virtue of their origin, they are able to produce 
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signicant amounts of human chorionic 
gonadotropin (hCG) which is a reliable tumour 
marker for diagnosis and monitoring of response 
1,2,4,5,6to treatment. 
There seems to be regional variations in the 
incidence of GTD world-wide. This is exemplied 
by the low rate of 23 per 100,000 pregnancies 
reported in Paraguay and the contrasting high 
rate of 1,299 per 100,000 pregnancies in 
7Indonesia.  Other rates include 66 per 100 000 
pregnancies in Italy, 122 per 100 000 pregnancies 
in the United States and 23 -265 cases per 100 000 
8pregnancies in South America.  A study to 
determine the incidence and pattern of GTD 
among Asians residing in Northern England and 
9
North Wales  reported that the Asian population 
had an incidence rate1.95 times higher than in the 
non Asian population (1 per 387 live births and 1 
per 752 live births respectively). Also, in Africa, a 
10
study carried out in Ethiopia  reported an 
incidence rate of 2.8 per 1000 deliveries while 
various studies in Nigeria had rates ranging from 
6,11-142.3 to 7.2/1000 deliveries.  Overall, about two-
third of these cases are attributed to molar 
pregnancy while the remaining third are due to 
1 , 4malignant forms of the disease.  These 
differences in the prevalence rates of gestational 
trophoblastic disease have been attributed to use 
of different criteria for classication of GTDs, 
8,9
clinical diagnosis and research methods.   
Signicant risk factors for the development of 
GTD are the age of the patient and previous 
history of Hydatidiform Mole(HM). Previous 
diagnoses with a hydatidiform mole confers a 1% 
risk of recurrence in subsequent pregnancies. This 
escalates to approximately 25% with more than 
1 11,14,15
one prior HM.  Some studies  reported that 
50% or more of cases of GTD had antecedent 
history of molar pregnancy while about 25% were 
seen to follow miscarriages or tubal pregnancy, 
and another 25% term or preterm pregnancy. 
Also, the risk of GTD appears to be more at the 
extremes of reproductive age however this 
association is seen much more with complete 
8,16
mole.  Women who are less than 16 years of age 
are six times more likely to develop the disease 
than women who fall within the 16-40years age 
range. Furthermore, there is a 17% risk of molar 
gestation in women who become pregnant at 50 
11, 16years or more.  Other factors that have been 
linked to development of GTD's include low 
economic status, deciency of vitamin A, protein, 
1 , 1 1 , 1 3folic acid and carotene ,  use of oral 
13,16contraceptives, parity,   and other unknown 
8
environmental factors.  
Gestational trophoblastic diseases most 
commonly present with amenorrhoea and 
vaginal bleeding. These are considered to be 
classical symptoms and was a consistent nding 
6,10,12,13in most studies  where they were recorded in 
up to 90 - 100% of patients. There are also reports 
6, 14
of uterine enlargement in about 50% of cases ,. 
Other symptoms and signs include, hyperemesis 
gravidarum, hyperthyroidism, preeclampsia 
1,4,8early in pregnancy and anaemia . A recent 
17study  however revealed that with increasing 
early diagnosis of complete mole, fewer women 
now present with these classical symptoms. This 
early diagnosis however has not been found to 
modify the risk of development of post molar 
GTN whose diagnosis is made based on the 
pattern of serum hCG concentrations measured 
during post molar follow-up after uterine 
evacuation. More than half of patients with post 
molar GTN maybe asymptomatic and those that 
do, manifest variable symptoms and signs. These 
clinical features however depend on the 
18
histological type and extent of the disease.  
The treatment of different GTDs depends on the 
specic type. Options include suction evacuation, 
chemotherapy, surgery and radiotherapy. 
Suction evacuation alone is most suited for 
Hydatidiform mole while cases of choriocarcinoma 
are amenable to chemotherapy or a combination 
of the various modalities based on the extent of 
1, 4
the disease and associated complications.  
Following treatment for GTD, follow up with 
serial measurements of b-Hcg is important. 
Unfortunately, this is a problem in resource poor 
settings where studies conducted reported high 
10,12
rates of loss to follow-up . This is signicant and 
is a major contributing factor to the pattern of 
presentation and outcome in these areas.
The diagnosis of cancer in our environment is one 
which is often not accepted by both patients and 
their relations. This perception may not be 
unrelated to the fact that many patients present 
late in the stage of the disease when outcome is not 
so favourable and reasons for this  late 
presentation may be due to patient and health 
system factors, including poor health seeking 
behaviour and unavailability of diagnostic tools 
15,19in the health system.  This situation is different 
from what is obtainable in advanced settings 
where cancer management and survival rates 
have greatly improved. In light of this and the 
need to improve patient outcome in our 
environment, the aim of this study was to report 
the prevalence and describe the pattern of 
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presentation, management practices and outcome 
of GTDs at the University of Abuja Teaching 
Hospital, Abuja, Nigeria. It is hoped that the 
information obtained will help guide formation of 
policies and establishment of protocols which are 
geared towards improving the morbidity and 
mortality associated with this disorder in our 
environment.
MATERIALS AND METHODS
This was a retrospective study of all cases of GTD 
managed over a period of 8 years at the University 
of Abuja Teaching Hospital, Abuja, Nigeria. The 
names and hospital numbers of consecutive cases 
st stof GTD managed between 1  January 2009 and 31  
December 2016 were obtained from registers in 
the theatre, gynaecological emergency unit, 
gynaecological clinic and the gynaecological 
ward. The labour ward and maternity ward 
registers also provided information on the 
number of deliveries per year for the same period 
of time. Information extracted and entered into 
structured proformas include sociodemographic 
characteristics, antecedent pregnancy, time 
period before presentation, symptoms and signs 
including complications, treatment modalities 
and follow-up duration. The data processing and 
analysis was done with the aid of SPSS for 
windows version 20.0. Results were expressed as 
percentages, means and standard deviation.
RESULTS
There was a total of 55 cases of Gestational 
Trophoblastic Diseases managed within this time 
period however, only 51 case les were retrieved 
and analysed. This gave a retrieval rate of 92.7%. 
During the study period, the total number of 
deliveries was 12,517. There were 30(58.8%) cases 
of molar pregnancy (26 complete moles and 4 
p a r t i a l  m o l e )  a n d  2 1 ( 4 1 . 2 % )  c a s e s  o f 
choriocarcinoma. This therefore puts the 
prevalence of GTDs at 0.44% or 4.4 per 1000 
deliveries while the prevalence of molar 
pregnancy and choriocarcinoma were 2.4 and 1.6 
per thousand deliveries [(1 in 416) and (1 in 625)] 
respectively.
Sociodemographic characteristics:
The mean age of the patients was 32.2 ± 8.5 years 
with a range of 20-50 years. Most of the patients 
with GTD were within the age group 25-29 years 
{18(35.3%)}. This was followed by 12(23.5%) 
patients who were aged 40 years and above. The 
lowest number of cases {5(9.8%)} were in the 30-
34year age group. The highest number of patients 
(36.7%) with molar pregnancy were in the 25-
29year age group while the highest number with 
choriocarcinoma (38.1%) were in the age group of 
40 years and above. This is shown in table 1.
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Table 1: Age distribution of patients with 
GTD in UATH, Abuja.





















Total 30(100 ) 21(100) 51(100)
Table 2: Parity distribution of patients 
with GTD.







0 12(40.0) 5(23.8) 17(33.3)
1-4 15(50.0) 10(47.6) 25(49.0)
≥5 3(10.0) 6(28.6) 9(17.6)
Total 30(100) 21(100) 51(100)
Table 2 shows the parity distribution of the Most 
(49%) of cases were para 1-4, followed by 
nulliparous women which constituted 33.3% of 
cases.
Table 3 highlights the other sociodemographic 
characteristics of the patients. Most of them were 
Christians (64.7%), married (90.2%) and 
housewives (37.3%). Although most (41.2%) of 
them were from a mixture of other tribes, the 
single most common ethnic group were the Igbos 
























Civil servant 2 3.9
Student 4 7.8







Table 3: Sociodemographic characteristics of 
patients with GTD.
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33(64.7%) patients was unknown as they were lost 
to follow up (Table 5). Ten patients died in the 
course of treatment giving a fatality rate of 19.6%. 
The average duration of symptoms before 
presentation for these mortality cases was 
14months (Range: 5-24 months). Nine had 
metastasis to one or two organ systems, 3 were on 
second line chemotherapy with EMACE and 
death usually occurred shortly after 1st course of 
chemotherapy.
Clinical Presentation:
The antecedent pregnancy events reported 
include miscarriage, live birth and molar 
pregnancy, seen in 38(74.5%), 12(23.5%) and 
1(2%) of patients respectively. The most common 
symptom at presentation was amenorrhoea 
46(90.2%), followed by vaginal bleeding 
45(88.2%), lower abdominal pain 21(41.2%) and 
passage of vesicles 9(17.65). Convulsion was seen 
in 2(3.9%) cases. The commonest sign was a large 
for gestational age uterus, seen in 27(52.9%) 
patients (See Table 4). Also, following laboratory 
investigations, 3(5.9%) of cases had metastases to 
the chest, 2(3.9%) to the brain and 6(11.8%) had 
metastases to more than one distant site.
Eighteen (35.5%) patients had anaemia (PCV less 
t h a n  3 0 % )  a t  p r e s e n t a t i o n  a n d  o t h e r 
complications recorded were shock and 



























Passage of vesicles 9 17.6
Dyspnoea 7 13.7




Large for GA uterus 27 52.9
Theca lutein cyst 8 15.7
Sub urethral nodules 5 9.8
Jaundice 1 2.0
Table 4: Clinical features of patients with GTD
at UATH, Abuja.
Treatment and follow-up:
Treatment comprised of either one or a 
combination of the following modes of treatment, 
suction evacuation, hysterectomy(TAH+BSO) 
and chemotherapy using the MAC, EMACO or 
EMACE regimen. Thirty (58.8%) patients had 
suction evacuation, 16(31.4%) had chemotherapy 
and 3(5.9%) had hysterectomy. Three (5.9%) 
p a t i e n t s  h a d  s u c t i o n  e v a c u a t i o n  a n d 
chemotherapy  whi le  2 (3 .9%)  had  both 
hysterectomy and chemotherapy. The 3 patients 
w h o  h a d  h y s t e r e c t o m y  w e r e  c a s e s  o f 
choriocarcinoma 
Overall, only 8(15.7%) patients had adequate 
follow up and were discharged. Outcome in 






























The prevalence of Gestational Trophoblastic 
Diseases (GTDs) in this study was 4.4 per 1000 
deliveries. This estimate is lower than 7.2 per 1000 
deliveries which was obtained in a study in Zaria 
6
(northern Nigeria),  higher than 2.3 per 1000 
deliveries reported in Port-harcourt (southern 
12Nigeria)  but similar to the 4.7 per 1000 births 
13
reported in Nnewi (eastern Nigeria).  These 
9gures when compared to UKs  rate of 1.4 per 
1000 live births show that this disorder is still 
common in our environment. 
This study noted a higher percentage of 
occurrence of molar pregnancy when compared 
t o  c h o r i o c a r c i n o m a ,  5 8 . 8 %  a n d  4 1 . 2 % 
respectively. This report is similar to reports of 
retrospective studies conducted in other centers 
12,13in Nigeria.  Other retrospective studies in 
10 15
Ethiopia  and Pakistan  reported signicantly 
higher percentages of occurrence of hydatidiform 
mole and another prospective observational 
study carried out in the UK reported that that 
choriocarcinoma occurred in only 0.9% of GTDs. 
Conversely, there were other retrospective 
studies done in Zaria and Nnewi in Nigeria where 
the percentage occurrence choriocarcinoma was 
more than that of HM. These comparisons are 
being made to support the observations made by 
9previous authors,  on the fact that the comparison 
of incidences between countries can be 
challenging due to inconsistencies in case 
Nigerian Journal of Medicine, Vol. 27  No.  4, October - December, 2018,  ISSN 1115-2613
346
detection by the different hospitals. Reasons for 
these may include both human and health system 
challenges and these are most predominant in 
settings like ours where patients present late or 
present to primary health centers where there is 
usually delay in diagnosis. There is also the issue 
of  unavai labi l i ty  or  unaf fordabi l i ty  of 
investigative tools. One of the solutions proffered 
was establishment of regional and/or national 
registration centers to ensure unbiased and 
9uniform data collection. 
The occurrence of GTD's have been reported to 
have a bimodal distribution of age with the 
highest risk seen in women under 16 years of age 
and higher risk also seen in women greater than 
16, 8,11, 9,13
40 years of age.   The ndings in this study 
did not follow this pattern because the highest 
risk was observed in the 25-29year age group. 
This nding is similar to that of a few other studies 
6,10, 19 and one possible reason for this nding is that 
there was no representation of patients 19 years 
and below in both our own study and theirs. 
About two thirds of the cases in our study were in 
women of low parity and this nding was similar 
15
to the nding of the study in Pakistan  but at 
10, 11, 14
variance with that of other studies.   Take for 
10example. The study done in Ethiopia  and 
14Ebonyi  reported that more than 50% of cases 
were seen in women who were para 5 and above. 
These variations in ndings may just be 
supportive of the fact that parity has not been 
13
identied as a signicant risk factor for GTDs.
Most commonly, GTN develops after a molar 
16
pregnancy  however this was not the case in this 
study as the commonest antecedent pregnancy 
event  for  both  hydat idi form mole  and 
choriocarcinoma was a miscarriage in about 77% 
and 71% of cases respectively. Only one case of 
choriocarcinoma was documented to have 
followed a molar pregnancy. One possible 
explanation for this might be the fact that our 
center, being a referral center have most patients 
presenting after having had some form of 
treatment from the referring facilities and these 
hospitals do not routinely send samples for 
histology following evacuation. So the history at 
presentation is usually that of an incomplete 
miscarriage with multiple uterine evacuations. It 
does not preclude the fact that some of these so 
called 'miscarriages' may have been even molar 
pregnancies from the onset, making this one of 
the limitations of our study. Also, this scenario 
forms part of the challenges in the denition and 
management of GTDs in resource poor settings 
and may also explain the relatively high 
occurrence of choriocarcinoma (41.2% of cases) in 
this study.
The commonest clinical features reported in this 
study were amenorrhoea, vaginal bleeding and a 
large for date uterus. These ndings are similar to 
those of other studies where as many as 90-100% 
of patients presented with amenorrhoea and 
13,11,10,6,14
vaginal bleeding  and more than half of the 
6, 20patients had large for date uteruses.  It is 
interesting to note that contrary to what is 
observed in these studies which are mainly from 
developing countries, the clinical presentation of 
molar pregnancy in developed countries has 
16changed over the past few decades  with fewer 
women presenting with these traditional signs 
and symptoms. Reason for this is early prenatal 
care in these climes with early beta human 
chorionic gonadotrophin (b-hCG) estimation and 
ultrasound scan (USS). Nonetheless, in the 
absence of this, it is important for health care 
practitioners at all levels to consider GTDs as a 
differential diagnosis early in the management of 
cases that present with these classical features. 
The most common complication reported in this 
study was anaemia and this nding, not 
surprisingly, is in agreement with the nding in 
most studies. Possible reasons for this include late 
presentation following abnormal uterine 
bleeding as was seen in our study, coupled with 
delay in making diagnosis and prompt referral. It 
could also be as a result of bleeding during the 
process of  evacuation or as a result  of 
1,4,16chemotherapy.  
The most common mode of treatment in this 
study was suction evacuation and this is the 
standard of care especially for patients with molar 
21
pregnancy . Chemotherapy use was relatively 
frequent because of the high proportion of cases 
with choriocarcinoma and it is also indicated in 
patients with molar pregnancy with persistent 
rise or plateau of b-HCG. This was reported in 
only two cases in this study. Prophylactic use of 
chemotherapy has remained a controversial issue 
1 but in the light of the poor health seeking 
behaviour and high rate of loss to follow up of 
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patients as seen in this study, and other studies 
10,12,14done in settings like ours  there may be need 
to consider this as an option in certain group of 
patients. Specic factors to be considered should 
include literacy level of the patient, level of 
ignorance with regard to health issues, economic 
ability, ability to communicate and access to 
standard health care. Hysterectomy is indicated 
in patients with a diagnosis of choriocarcinoma 
especially if they are older women who have 
completed family size or in patients with 
6
intractable haemorrhage.  In our study, two of the 
patients who had hysterectomy were older 
women who had completed family size and the 
third was a younger woman with intractable 
haemorrhage. 
In this study, the nal outcome of the disease was 
not known in a signicant proportion of the 
patients and this is a limitation of the study.  
Similar and even higher gures than ours have 
10,12,14,15
been reported in other studies,  especially 
those  done in  s imilar  set t ings  and the 
multifaceted reasons for these have been 
highlighted previously. It is expected that 
patients with a diagnosis of molar pregnancy be 
followed up for a period of 6-12 months and those 
1,16
with choriocarcinoma be followed up for life.  
The mortality rate of 19.6% recorded in this study 
is higher than reports from studies conducted in 
6,11,12,13other parts of Nigeria  and reasons for this 
may be the fact that our center is a referral center 
for neighbouring states. A signicantly lower 
mortality rate of 0.84% was reported by a 
22retrospective study conducted in Argentina  
while analysis of survival rates of high-risk 
gestational trophoblastic neoplasia (GTN) 
patients treated over a 15-year period at the 
Charing Cross Gestational Trophoblastic Disease 
23
Centre, UK  reported an overall mortality rate of 
6%, most of which were from drug resistance. 
These reports highlight the excellent prognosis of 
the disease in the presence of early diagnosis, 
adequate treatment and good compliance, 
especially in the setting of well-established 
centers. 
CONCLUSION
Morbidity and mortality resulting from GTDs is 
still high in our environment. There was late 
presentation and poor compliance of patients in 
this study. It is therefore important to reeducate 
health care workers on the disease so as to 
improve early diagnosis and referral.  There is 
also need to reinforce education and counselling 
of patients so as to improve compliance. 
Establishing a system that could ensure a system 
of recall could also help improve compliance. 
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